Versor Investments LP Makes New Investment in Encompass Health Co. (NYSE:EHC)

Versor Investments LP acquired a new stake in shares of Encompass Health Co. (NYSE:EHC) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 9,500 shares of the company’s stock, valued at approximately $634,000.

A number of other large investors have also modified their holdings of EHC. International Assets Investment Management LLC bought a new stake in shares of Encompass Health in the 4th quarter valued at approximately $20,210,000. Jackson Creek Investment Advisors LLC grew its position in Encompass Health by 364.4% in the fourth quarter. Jackson Creek Investment Advisors LLC now owns 13,910 shares of the company’s stock valued at $928,000 after acquiring an additional 10,915 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Encompass Health by 2.3% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,318,784 shares of the company’s stock worth $87,989,000 after acquiring an additional 29,926 shares in the last quarter. Phocas Financial Corp. lifted its holdings in shares of Encompass Health by 112.4% during the fourth quarter. Phocas Financial Corp. now owns 99,875 shares of the company’s stock valued at $6,664,000 after acquiring an additional 52,847 shares during the period. Finally, Nordea Investment Management AB boosted its stake in shares of Encompass Health by 21.0% in the 4th quarter. Nordea Investment Management AB now owns 101,705 shares of the company’s stock valued at $6,787,000 after purchasing an additional 17,684 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EHC has been the subject of a number of recent analyst reports. Truist Financial increased their target price on shares of Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Friday, February 9th. William Blair reissued an “outperform” rating on shares of Encompass Health in a report on Wednesday, February 7th. Royal Bank of Canada restated an “outperform” rating and set a $83.00 price target on shares of Encompass Health in a research report on Friday, February 9th. Mizuho lifted their price objective on Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Finally, Stephens restated an “overweight” rating and set a $85.00 target price on shares of Encompass Health in a report on Tuesday, January 16th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Encompass Health presently has an average rating of “Buy” and an average target price of $90.29.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, CEO Mark J. Tarr sold 44,976 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the completion of the sale, the chief executive officer now owns 554,098 shares in the company, valued at approximately $46,139,740.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP John Patrick Darby sold 14,543 shares of Encompass Health stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $83.94, for a total transaction of $1,220,739.42. Following the transaction, the executive vice president now owns 84,773 shares of the company’s stock, valued at approximately $7,115,845.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark J. Tarr sold 44,976 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now owns 554,098 shares of the company’s stock, valued at approximately $46,139,740.46. The disclosure for this sale can be found here. Insiders own 2.10% of the company’s stock.

Encompass Health Stock Performance

EHC stock opened at $86.53 on Friday. The company has a 50 day moving average price of $80.24 and a 200 day moving average price of $72.38. The stock has a market capitalization of $8.71 billion, a PE ratio of 23.39, a price-to-earnings-growth ratio of 1.35 and a beta of 0.92. Encompass Health Co. has a fifty-two week low of $57.55 and a fifty-two week high of $86.72. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.37.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same period last year, the company earned $0.88 earnings per share. The company’s revenue was up 13.4% on a year-over-year basis. Analysts forecast that Encompass Health Co. will post 4.09 EPS for the current year.

Encompass Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Monday, July 1st will be issued a $0.15 dividend. The ex-dividend date is Friday, June 28th. This represents a $0.60 annualized dividend and a yield of 0.69%. Encompass Health’s dividend payout ratio is currently 16.22%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.